These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 673774)

  • 1. [Survey of anthracyclines derivatives in haematology (author's transl)].
    Jacquillat C; Weil M; Auclerc MF; Maral J; Schaison G; Boiron M; Bernard J
    Nouv Presse Med; 1978 Jun; 7(23):2061-6. PubMed ID: 673774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
    Jaenke RS; Deprez-DeCampeneere D; Trouet A
    Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical activity of detorubicin: a new anthracycline derivative.
    Jacquillat C; Auclerc MF; Weil M; Maral J; Degos L; Auclerc G; Tobelem G; Schaison G; Bernard J
    Cancer Treat Rep; 1979 May; 63(5):889-93. PubMed ID: 455330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
    Marie JP; Thevenin D; Zittoun R
    Nouv Rev Fr Hematol (1978); 1985; 27(3):163-7. PubMed ID: 3862071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
    Haruyama H; Shimazaki C; Nakanishi S; Hamami T; Nisio A; Isemura T; Katsume H; Nakagawa M; Ijichi H
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental evaluation of anthracycline analogs.
    Casazza AM
    Cancer Treat Rep; 1979 May; 63(5):835-44. PubMed ID: 455325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Models of preclinical studies of anthracyclines].
    Fizames C
    Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of acute leukemia in the adult. Role of anthracyclines].
    Gisselbrecht C; Lepage E; Lenoble M; Marty M; Boiron M
    Pathol Biol (Paris); 1987 Jan; 35(1):69-74. PubMed ID: 3550615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical studies with daunorubicin-DNA and adriamycin-DNA complexes: a review.
    Trouet A; Sokal G
    Cancer Treat Rep; 1979 May; 63(5):895-8. PubMed ID: 287556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical pharmacology of idarubicin].
    Robak T
    Acta Haematol Pol; 1993; 24(4):315-26. PubMed ID: 8303977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rubidazone (22 050 RP): clinical study. Phase II trial in solid tumors and lymphomas (author's transl)].
    Chauvergne J; Cappelaere P; Carton M; Gary-Bobo J; Klein T
    Bull Cancer; 1978; 65(1):19-24. PubMed ID: 667371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study.
    Bickers J; Benjamin R; Wilson H; Eyre H; Hewlett J; McCredie K
    Cancer Treat Rep; 1981; 65(5-6):427-30. PubMed ID: 6940659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
    Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
    Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
    Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
    Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the toxicity and therapeutic efficacy of daunorubicin linked with a biodegradable carrier.
    Hrdina R; Bogusová TA; Kunová A; Kvĕtina J
    Neoplasma; 1991; 38(3):265-73. PubMed ID: 1857447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia.
    Zhang G; Fang L; Zhu L; Zhong Y; Wang PG; Sun D
    J Med Chem; 2006 Mar; 49(5):1792-9. PubMed ID: 16509594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of daunorubicin in induction therapy for adult acute myeloid leukemia].
    Usui N; Dobashi N; Asai O; Yano S; Kato A; Osawa H; Uno S; Katori M; Nagamine M; Yahagi Y; Yamaguchi Y; Saito T; Kasama K; Takei Y; Ogihara A; Yamazaki H; Kobayashi T; Tajima N; Ogawa M; Kuraishi Y
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1152-9. PubMed ID: 10945010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
    Young CW; Raymond V
    Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
    Johnson RK; Chitnis MP; Embrey WM; Gregory EB
    Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.